PDR Network Introduces New Adverse Drug Event Reporting System
PDR Network introduces RxEvent, a new online network to collect and distribute adverse drug events now available to all US prescribers via integration into electronic health record platforms and other online services, including directly at www.RxEvent.org.
Roughly half a million adverse drug events are reported annually to the FDA, with over 90 percent of these reports coming from pharmaceutical manufacturers who receive them from physicians and other providers via telephone. This legacy call center-based system is expensive for manufacturers and inconvenient and time-consuming by physicians; it is not surprising that studies show as few as one in ten ADEs are actually reported by healthcare professionals due to this cumbersome process. RxEvent addresses this issue by offering physicians a new way to report ADEs quickly and easily from within their workflow to improve the quality, timeliness, and overall reporting of adverse events.
RxEvent benefits include:
· Decreasing costs associated with current call centers and backend manual processing and reporting;
· Improving reporting quality and rates by physicians and pharmacists by placing the system within their workflow;
· Increasing data mining value through report customization and electronic data gathering; and
· Allowing for monitoring of off-label use and new side effects developing with approved use.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
